// App-Quantinova.ai

155 : Differences in Quality of Life Between Bendamustine Plus Rituximab Compared with Standard First-Line Treatments in Patients with Previously Untreated Advanced Indolent Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma

Researchers

Presenter

  • Richard H. van der Jagt

Principal Investigators

  • Brad S. Kahl

  • Samar Issa

  • Richard E. White

  • Mihaela C. Munteanu

  • Sang-Hoon

  • Regina Clementi

  • Ling Chen

  • Ian W. Flinn

  • Peter Wood

  • Tim E. Hawkins

  • David MacDonald

  • Mark Hertzberg

  • Yiu-Lam Kwan

  • David Simpson

  • Michael Craig

  • Kathryn Kolibaba

Medical Centers

  • Hematology Department, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia

  • Gastroenterology, Auckland Hospital, Auckland, New Zealand

  • Westmead hospital, Sydney, New South Wales, Australia

  • Clin Operations, Oncology & Haematology/Lymphoma Service, Middlemore Hospital, Auckland , New Zealand

  • Hematology, QEII Health Sciences and Capital District Health Authority, Halifax, NS, Canada

  • Haematology, North Shore Hospital, Auckland, New Zealand

  • University of Ottawa, Canadian Leukemia Studies Group at Ottawa Hospital, Ottawa, ON, Canada

  • Concord Repatriation General Hospital, New South Wales, Australia

Locations

  • Canada

  • New Zealand

  • Australia

Companies

  • Teva Pharmaceutical

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • B-Cell Non-Hodgkin Lymphoma

  • Chronic Lymphocytic Leukemia

  • Non-Hodgkin's Lymphoma

  • Mantle cell lymphoma

  • Hodgkin's Lymphoma

  • Constipation

  • Non‐Hodgkin Lymphoma

  • Lymphomas

  • Insomnia

  • Dyspnea

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Bendamustine

  • Vincristine

  • Doxorubicin

  • Prednisone

  • Rituximab

Outcome

  • N/A

Study Design

  • randomized

  • double blind/blinded

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved